Mediclinic International Plc

Public consensus   -   Last updated 22/09/21

Reporting currency: GBP
Reporting unit: Absolute
 
NO. OF
FORECASTS
FY24
CONSENSUS
22/09/21
FY24
MIN
FY24
MAX
Hirslanden (CHF'm) - Adjusted
Revenue
13
1,898
1,840
2,014
EBITDA
13
316
277
346
EBITDA margin (%)
13
16.6
15.0
18.0
Average FX rate GBP/CHF
13
1.26
1.19
1.41
Southern Africa (ZAR'm) - Adjusted
Revenue
13
19,435
18,184
21,231
EBITDA
13
3,951
3,263
4,461
EBITDA margin (%)
13
20.3
17.5
22.1
Average FX rate GBP/ZAR
13
20.69
19.19
22.05
Middle East (AED'm) - Adjusted
Revenue
13
4,311
4,054
4,440
EBITDA
13
697
632
776
EBITDA margin (%)
13
16.2
15.0
17.5
Average FX rate GBP/AED
13
5.04
4.80
5.40
Adjusted Group (GBP'm)
Revenue
13
3,303
3,187
3,443
EBITDA
13
578
544
620
EBITDA margin (%)
13
17.5
16.9
18.3
D&A
13
(227)
(256)
(207)
Operating profit
13
351
325
410
Net finance cost
13
(68)
(105)
(42)
Share of profit of equity accounted investment
10
9
4
13
Earnings (equity holders)
13
213
191
253
Earnings per share (pence)
13
28.8
25.9
34.4
Dividend per share (pence)
13
7.9
6.5
10.0
Net Debt
13
1,607
615
1,989
Net cash generated from operating activities
12
446
405
497
Total Group Capex
13
204
160
260

Disclaimer

Mediclinic International plc (“Mediclinic”) does not endorse or adopt any of the consensus estimates expressed in this report. The report represents the views of analysts from which the consensus estimates are derived. Mediclinic will not provide any commentary on the consensus or answer questions on it. The circulation of the consensus by Mediclinic is not mandatory and Mediclinic may amend its practice on this at any time.